Skip to main content

Change to Mixed-Lipid Emulsion From Soybean Oil-Based Lipid Emulsion in Pediatric Patients.

Publication ,  Journal Article
Haines, KL; Ohnuma, T; Hornik, CD; Grisel, B; Leraas, H; Trujillo, CN; Krishnamoorthy, V; Raghunathan, K; Wischmeyer, PE
Published in: JAMA Netw Open
September 5, 2023

IMPORTANCE: Critically ill pediatric patients often require parenteral nutrition (PN) in the intensive care unit (ICU). Literature suggests mixed lipid emulsions (LE) with soybean oil reduction strategies may improve outcomes. OBJECTIVE: To examine the association of a hospital-wide switch to a mixed-lipid formula (4-OLE) with pediatric outcomes. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study at a large US academic referral center. Pediatric patients aged 1 month to 17 years requiring parenteral nutrition from May 2016 to September 2019 were included. Data were analyzed from October 2020 to February 2023. EXPOSURE: In 2017, Duke University Health System fully converted to a soybean oil/MCT/olive/fish oil lipid (4-OLE) from pure soybean oil-based LE in pediatric patients. Pediatric patients before the change (Intralipid [IL] group) were compared with patients after (4-OLE group). MAIN OUTCOMES AND MEASURES: Clinical outcomes were compared between treatment periods via multivariable regression models. The primary outcome was hospital length of stay (LOS). Fourteen secondary outcomes included hospital mortality of any cause, 30-day or 90-day readmission, pneumonia, urinary tract infections (UTIs), total caloric delivery, and liver function tests (aspartate aminotransferase, alanine transaminase, alkaline phosphatase, and total bilirubin). RESULTS: A total of 684 children dependent on PN were identified (342 were critically ill), with 30% (206 children) in the preswitch (IL) period and 70% (478 children) in the postswitch (4-OLE) period; 123 were male (59.7%). In comparing IL vs 4-OLE, there was a significant difference in median (IQR) age (4.0 [1.2-13.0] vs 3.0 [0.8-9.0] years, respectively; P = .04), without difference in body mass index or baseline comorbidities except for significant differences in cancer diagnosis (26 patients in the IL group [12.6%] vs 29 patients in the 4-OLE group [6.1%]; P = .004) and chronic obstructive pulmonary disease (24 patients in the IL group [11.7%] vs 30 patients in the 4-OLE group [6.3%]; P = .02). In the all children cohort, 4-OLE was associated with shorter hospital LOS (IRR, 0.81; 95% CI, 0.05-0.78), and reduced UTI risk (OR, 0.33; 95% CI, 0.18-0.64). In the ICU cohort, 4-OLE was associated with shorter hospital LOS (IRR, 0.81; 95% CI, 0.78-0.83), and reduced UTI risk (OR, 0.23; 95% CI, 0.11-0.51). Other secondary outcomes were not significant. CONCLUSIONS AND RELEVANCE: In this observational study of clinical outcomes among children dependent on PN, a switch to 4-OLE in a large academic hospital was associated with a significant decrease in hospital LOS in ICU and non-ICU patients. These findings suggest switching to a soy-LE sparing strategy using 4-OLE is feasible, safe, and associated with improved clinical outcomes in pediatric PN patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA Netw Open

DOI

EISSN

2574-3805

Publication Date

September 5, 2023

Volume

6

Issue

9

Start / End Page

e2332389

Location

United States

Related Subject Headings

  • Soybean Oil
  • Retrospective Studies
  • Male
  • Infant
  • Humans
  • Female
  • Emulsions
  • Critical Illness
  • Child, Preschool
  • Child
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Haines, K. L., Ohnuma, T., Hornik, C. D., Grisel, B., Leraas, H., Trujillo, C. N., … Wischmeyer, P. E. (2023). Change to Mixed-Lipid Emulsion From Soybean Oil-Based Lipid Emulsion in Pediatric Patients. JAMA Netw Open, 6(9), e2332389. https://doi.org/10.1001/jamanetworkopen.2023.32389
Haines, Krista L., Tetsu Ohnuma, Chi Dang Hornik, Braylee Grisel, Harold Leraas, Charles N. Trujillo, Vijay Krishnamoorthy, Karthik Raghunathan, and Paul E. Wischmeyer. “Change to Mixed-Lipid Emulsion From Soybean Oil-Based Lipid Emulsion in Pediatric Patients.JAMA Netw Open 6, no. 9 (September 5, 2023): e2332389. https://doi.org/10.1001/jamanetworkopen.2023.32389.
Haines KL, Ohnuma T, Hornik CD, Grisel B, Leraas H, Trujillo CN, et al. Change to Mixed-Lipid Emulsion From Soybean Oil-Based Lipid Emulsion in Pediatric Patients. JAMA Netw Open. 2023 Sep 5;6(9):e2332389.
Haines, Krista L., et al. “Change to Mixed-Lipid Emulsion From Soybean Oil-Based Lipid Emulsion in Pediatric Patients.JAMA Netw Open, vol. 6, no. 9, Sept. 2023, p. e2332389. Pubmed, doi:10.1001/jamanetworkopen.2023.32389.
Haines KL, Ohnuma T, Hornik CD, Grisel B, Leraas H, Trujillo CN, Krishnamoorthy V, Raghunathan K, Wischmeyer PE. Change to Mixed-Lipid Emulsion From Soybean Oil-Based Lipid Emulsion in Pediatric Patients. JAMA Netw Open. 2023 Sep 5;6(9):e2332389.

Published In

JAMA Netw Open

DOI

EISSN

2574-3805

Publication Date

September 5, 2023

Volume

6

Issue

9

Start / End Page

e2332389

Location

United States

Related Subject Headings

  • Soybean Oil
  • Retrospective Studies
  • Male
  • Infant
  • Humans
  • Female
  • Emulsions
  • Critical Illness
  • Child, Preschool
  • Child